DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Dejeux, Emelyne ^a   Rønneberg, Jo A ^b,c   Solvang, Hiroko ^c,d   Bukholm, Ida ^c,e   Geisler, Stephanie ^f   Aas, Turid ^f   Gut, Ivo G ^a   Børresen Dale, Anne Lise ^b,c   Lønning, Per E ^f,g   Kristensen, Vessela N ^b,c   Tost, Jörg ^a  

^a CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Akerhus University Hospital   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; F BOX AND WD REPEAT CONTAINING PROTEIN 7; F BOX PROTEIN; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; P CADHERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R2B PROTEIN; PROGESTERONE RECEPTOR; PROTEIN MLH1; PROTEIN P53; SOMATOMEDIN B; TAMOXIFEN; TRANSCRIPTION FACTOR FOXC1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; DISTANT METASTASIS; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PROGNOSIS; PROMOTER REGION; TREATMENT RESPONSE; TUMOR VOLUME; BREAST TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA METHYLATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC;

EID: 77952248685     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-68     Document Type: Article

References (52)

1. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672. 10.1038/nrc2193, 17721431.
2. Lonning PE. Breast cancer prognostication and prediction: are we making progress?. Ann Oncol 2007, 18(Suppl 8):viii3-7. 10.1093/annonc/mdm260, 17890212.
3. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413. 10.1038/sj.onc.1205651, 12154403.
4. Laird PW. Cancer epigenetics. Hum Mol Genet 2005, 14(Spec No 1):R65-76. 10.1093/hmg/ddi113, 15809275.
5. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002, 21:5462-5482. 10.1038/sj.onc.1205606, 12154408.
6. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000, 6:1432-1438.
7. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004, 10:5349-5354. 10.1158/1078-0432.CCR-04-0555, 15328171.
8. Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A, Ordway JM, McCombie WR, Leon J, Jeddeloh JA, McPherson JD. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res 2008, 18:19-29. 10.1101/gr.6883307, 2134785, 18032725.
9. Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD, Jeddeloh JA. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS ONE 2007, 2:e1314. 10.1371/journal.pone.0001314, 2117343, 18091988.
10. Ronneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, Yakhini Z, Gut IG, Lonning PE, Borresen-Dale AL, Gabrielsen OS, Kristensen VN. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res 2008, 68:5562-5571. 10.1158/0008-5472.CAN-07-5828, 18632608.
11. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, Nelson WG. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Therap 2004, 3:540-548.
12. Vo QN, Kim WJ, Cvitanovic L, Boudreau DA, Ginzinger DG, Brown KD. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 2004, 23:9432-9437. 10.1038/sj.onc.1208092, 15516988.
13. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-3229.
14. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005, 11:5869-5877. 10.1158/1078-0432.CCR-05-0059, 16115928.
15. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998, 58:2515-2519.
16. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998, 58:4515-4518.
17. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996, 93:11757-11762. 10.1073/pnas.93.21.11757, 38131, 8876210.
18. Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Manning J, Herman JG, Davidson NE. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Therap 2004, 3:1304-1312.
19. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004, 41:117-124. 10.1002/gcc.20062, 15287024.
20. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, Koyanagi K, Hoon DS. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005, 65:1800-1807. 10.1158/0008-5472.CAN-04-3531, 15753377.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
22. Akhoondi S, Sun D, Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012. 10.1158/0008-5472.CAN-07-1320, 17909001.
23. Raguz S, Tamburo De Bella M, Tripuraneni G, Slade MJ, Higgins CF, Coombes RC, Yague E. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004, 10:2776-2783. 10.1158/1078-0432.CCR-03-0517, 15102684.
24. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61:2505-2512.
25. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer 2008, 7:15. 10.1186/1476-4598-7-15, 2246151, 18221536.
26. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26:2126-2132. 10.1038/sj.onc.1210014, 17016441.
27. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64:3807-3813. 10.1158/0008-5472.CAN-03-3852, 15172987.
28. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007, 9:R57. 10.1186/bcr1762, 2206733, 17764565.
29. Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Heikkila P, Egilsson V, Olsson H, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer 2006, 119:1052-1060. 10.1002/ijc.21934, 16570289.
30. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Lønning PE, Kaaresen R, Gray JW. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA 2001, 98:7952-7957. 10.1073/pnas.151241198, 35449, 11438741.
31. Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lonning PE, Borresen-Dale AL, Kristensen VN. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 2007, 17:127-136. 10.1097/FPC.0b013e328011abaa, 17301692.
32. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008, 324:95-102. 10.1124/jpet.107.127704, 17947497.
33. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997, 3:2025-2032.
34. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003, 10:43-73. 10.1677/erc.0.0100043, 12653670.
35. Pajic M, Iyer JK, Kersbergen A, Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 2009, 69:6396-6404. 10.1158/0008-5472.CAN-09-0041, 19654309.
36. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005, 280:20310-20315. 10.1074/jbc.M500737200, 15784621.
37. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8:1061-1067.
38. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006, 24:2428-2436. 10.1200/JCO.2005.02.9264, 16682728.
39. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13:1198-1207. 10.1158/1078-0432.CCR-06-1304, 17317830.
40. Fontaniere S, Tost J, Wierinckx A, Lachuer J, Lu J, Hussein N, Busato F, Gut I, Wang ZQ, Zhang CX. Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis. Endocr Relat Cancer 2006, 13:1223-1236. 10.1677/erc.1.01294, 17158767.
41. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007, 7:847-859. 10.1038/nrc2223, 17943136.
42. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Borresen-Dale AL. Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res 2007, 9:R5. 10.1186/bcr1637, 1851401, 17224074.
43. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak K. Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 2008, 105:14076-14081. 10.1073/pnas.0805206105, 2532972,2532972, 18780791.
44. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL, Weinberg RA. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007, 104:10069-10074. 10.1073/pnas.0703900104, 1891217, 17537911.
45. Kalinina EV, Chernov NN, Saprin AN, Kotova YN, Remizov VI, Shcherbak NP. Expression of genes for redox-dependent glutathione S-transferase isoforms GSTP1-1 and GSTA4-4 in tumor cell during the development doxorubicin resistance. Bull Exp Biol Med 2007, 143:328-330. 10.1007/s10517-007-0102-2, 18225754.
46. Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, Lazarous DF, Pierce L, d'Angelo T, Moscow JA, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993, 11:49-58.
47. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 2003, 16:558-565. 10.1097/01.MP.0000071842.83169.5A, 12808061.
48. Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Borresen-Dale AL, Lillehaug JR, Lonning PE. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res 2006, 12:6000-6004. 10.1158/1078-0432.CCR-05-2822, 17062672.
49. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol Biol 2005, 291:207-216.
50. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45:1033-1040. 10.1002/gcc.20366, 16897746.
51. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007, 2:2265-2275. 10.1038/nprot.2007.314, 17853883.
52. Akaike H. Information theory and extension of the maximum likelihood principle. Akademia Kiado, Budapest 1973, 267-281. Petrov N, Csaki F.